Cited 0 times in
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2021-09-29T00:34:20Z | - |
dc.date.available | 2021-09-29T00:34:20Z | - |
dc.date.issued | 2020-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183920 | - |
dc.description.abstract | Background: By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world practice. Methods: This is a multi-institutional study enrolled the patients with stage III to IVB LA-HNSCC, except for nasopharyngeal carcinoma, from 2004 to 2015 in thirteen referral hospitals capable of multidisciplinary care. Results: A total of 445 LA-HNSCC patients were analyzed. The median age was 61 years (range, 24-89). The primary tumor location was the oropharynx in 191 (43%), oral cavity in 106 (24%), hypopharynx in 64 (14%), larynx in 57 (13%) and other sites in 27 (6%). The most common stage was T2 in 172 (39%), and N2 in 245 (55%). Based on treatment intents, 229 (52%) of the patients received definitive concurrent chemoradiotherapy (CCRT) and 187 (42%) underwent surgery. Approximately 158 (36%) of the study population received induction chemotherapy (IC). Taken together, 385 (87%) of the patients underwent combined therapeutic modalities. The regimen for definitive CCRT was weekly cisplatin in 58%, 3-weekly cisplatin in 28% and cetuximab in 3%. The preferred regimen for IC was docetaxel with cisplatin in 49%, and docetaxel, cisplatin plus fluorouracil in 27%. With a median follow-up of 39 months, one-year and two-year survival rates were 89 and 80%, respectively. Overall survival was not significantly different between CCRT and surgery group (p = 0.620). Conclusions: In patients with LA-HNSCC, the majority of patients received combined therapeutic modalities. Definitive CCRT, IC then definitive CCRT, and surgery followed by adjuvant CCRT or radiotherapy are the preferred multidisciplinary strategies in real-world practice. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antimetabolites, Antineoplastic / therapeutic use* | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use* | - |
dc.subject.MESH | Cetuximab / therapeutic use* | - |
dc.subject.MESH | Chemoradiotherapy / methods* | - |
dc.subject.MESH | Cisplatin / therapeutic use* | - |
dc.subject.MESH | Combined Modality Therapy / methods* | - |
dc.subject.MESH | Docetaxel / therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil / therapeutic use* | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Head and Neck Neoplasms / drug therapy* | - |
dc.subject.MESH | Head and Neck Neoplasms / mortality | - |
dc.subject.MESH | Head and Neck Neoplasms / surgery | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Induction Chemotherapy / methods* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / drug therapy* | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / mortality | - |
dc.subject.MESH | Squamous Cell Carcinoma of Head and Neck / surgery | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Young Adult | - |
dc.title | Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yun-Gyoo Lee | - |
dc.contributor.googleauthor | Eun Joo Kang | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Jin-Hyuk Choi | - |
dc.contributor.googleauthor | Jin-Soo Kim | - |
dc.contributor.googleauthor | Keon Uk Park | - |
dc.contributor.googleauthor | Kyoung Eun Lee | - |
dc.contributor.googleauthor | Jung Hye Kwon | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Hee Kyung Ahn | - |
dc.contributor.googleauthor | Seong Hoon Shin | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Hwan Jung Yun | - |
dc.identifier.doi | 10.1186/s12885-020-07297-z | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J00351 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.identifier.pmid | 32854649 | - |
dc.subject.keyword | Locally advanced head and neck cancer | - |
dc.subject.keyword | Multidisciplinary treatment | - |
dc.subject.keyword | Squamous cell carcinoma | - |
dc.subject.keyword | Strategy | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 813 | - |
dc.identifier.bibliographicCitation | BMC CANCER, Vol.20(1) : 813, 2020-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.